Pub Date : 2018-05-01Epub Date: 2018-05-24DOI: 10.21037/apc.2018.05.01
Efrat Dotan
{"title":"Can computational modeling help in personalizing the care of patients with pancreatic ductal adenocarcinoma?","authors":"Efrat Dotan","doi":"10.21037/apc.2018.05.01","DOIUrl":"https://doi.org/10.21037/apc.2018.05.01","url":null,"abstract":"","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/apc.2018.05.01","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38099207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
On June 17, 2018, the 4 th International HBP Surgery Forum successfully ended, after a 4-day scientific agenda. The event took place in Hangzhou, a beautiful city located in China. With the presence of so many prestigious local and foreign experts, it has been an excellent conference, which is helpful to the therapy of hepatobiliary and pancreatic tumors, hepatic and gall diseases and pancreatic diseases and also enhances the exchange of ERAS, MDT and the relevant researches.
{"title":"Prof. Min Li: three heads are better than one","authors":"Hailing Lian, Molly J. Wang","doi":"10.21037/apc.2018.08.04","DOIUrl":"https://doi.org/10.21037/apc.2018.08.04","url":null,"abstract":"On June 17, 2018, the 4 th International HBP Surgery Forum successfully ended, after a 4-day scientific agenda. The event took place in Hangzhou, a beautiful city located in China. With the presence of so many prestigious local and foreign experts, it has been an excellent conference, which is helpful to the therapy of hepatobiliary and pancreatic tumors, hepatic and gall diseases and pancreatic diseases and also enhances the exchange of ERAS, MDT and the relevant researches.","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82031356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01Epub Date: 2018-02-27DOI: 10.21037/apc.2018.02.01
Amar B Deshwar, Elizabeth Sugar, Deirdre Torto, Ana De Jesus-Acosta, Matthew J Weiss, Christopher L Wolfgang, Dung Le, Jin He, Richard Burkhart, Lei Zheng, Daniel Laheru, Mark Yarchoan
Background: Pancreatic ductal adenocarcinoma (PDAC) often presents with nonspecific symptoms and the workup is not standardized. To study the impact of delays in diagnosis and in the initiation of treatment, we investigated the relationship between length of diagnostic intervals and surgical resectability.
Methods: We performed a retrospective chart review of patients evaluated for PDAC at Johns Hopkins in 2014. Data were collected on the patient (date of first symptoms-first medical appointment), diagnostic (first medical appointment-diagnosis of PDAC), and treatment (diagnosis of PDAC-1st day of treatment) time intervals, and the upfront treatment received. Asymptomatic patients diagnosed incidentally, or for whom records were incomplete, were excluded from analysis.
Results: Of 453 charts reviewed, 116 patients met inclusion criteria. The median patient interval was 14 days [interquartile range (IQR): 6-30 days], the median diagnostic interval was 22 days (IQR: 8-46 days), and the median treatment interval was 26 days (IQR: 15-35 days). Thirty-eight patients (33%) received upfront surgery and 78 (67%) received nonsurgical treatment. After adjusting for multiple factors, the odds of receiving surgery significantly increased for individuals with a patient interval of 30 days or less [adjusted odds ratio (aOR): 3.41; 95% confidence interval (CI): 1.08-13.20; P=0.050] and with a diagnostic interval of 60 days or less (aOR: 15.68; 95% CI: 2.95-291.00, P=0.009).
Conclusions: A patient interval less than 1 month and a diagnostic interval less than 2 months for symptomatic PDAC are associated with increased odds of upfront surgical resection. These data provide initial evidence that reducing diagnostic delays may lead to improved outcomes in PDAC.
{"title":"Diagnostic intervals and pancreatic ductal adenocarcinoma (PDAC) resectability: a single-center retrospective analysis.","authors":"Amar B Deshwar, Elizabeth Sugar, Deirdre Torto, Ana De Jesus-Acosta, Matthew J Weiss, Christopher L Wolfgang, Dung Le, Jin He, Richard Burkhart, Lei Zheng, Daniel Laheru, Mark Yarchoan","doi":"10.21037/apc.2018.02.01","DOIUrl":"https://doi.org/10.21037/apc.2018.02.01","url":null,"abstract":"<p><strong>Background: </strong>Pancreatic ductal adenocarcinoma (PDAC) often presents with nonspecific symptoms and the workup is not standardized. To study the impact of delays in diagnosis and in the initiation of treatment, we investigated the relationship between length of diagnostic intervals and surgical resectability.</p><p><strong>Methods: </strong>We performed a retrospective chart review of patients evaluated for PDAC at Johns Hopkins in 2014. Data were collected on the patient (date of first symptoms-first medical appointment), diagnostic (first medical appointment-diagnosis of PDAC), and treatment (diagnosis of PDAC-1st day of treatment) time intervals, and the upfront treatment received. Asymptomatic patients diagnosed incidentally, or for whom records were incomplete, were excluded from analysis.</p><p><strong>Results: </strong>Of 453 charts reviewed, 116 patients met inclusion criteria. The median patient interval was 14 days [interquartile range (IQR): 6-30 days], the median diagnostic interval was 22 days (IQR: 8-46 days), and the median treatment interval was 26 days (IQR: 15-35 days). Thirty-eight patients (33%) received upfront surgery and 78 (67%) received nonsurgical treatment. After adjusting for multiple factors, the odds of receiving surgery significantly increased for individuals with a patient interval of 30 days or less [adjusted odds ratio (aOR): 3.41; 95% confidence interval (CI): 1.08-13.20; P=0.050] and with a diagnostic interval of 60 days or less (aOR: 15.68; 95% CI: 2.95-291.00, P=0.009).</p><p><strong>Conclusions: </strong>A patient interval less than 1 month and a diagnostic interval less than 2 months for symptomatic PDAC are associated with increased odds of upfront surgical resection. These data provide initial evidence that reducing diagnostic delays may lead to improved outcomes in PDAC.</p>","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/apc.2018.02.01","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36033152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：